From Prototype to Profit: Commercialization Insights

Olema Oncology announced a public offering to fund late-stage breast cancer trials, navigating a crowded SERD market and balancing growth with financial prudence. Is this a promising venture or a risky bet?

A single patient's dramatic response to a novel combination therapy offers a potential breakthrough in treating triple-negative breast cancer, but the Australian biotech faces a crucial Nasdaq delisting battle.

Acurx Pharmaceuticals secures ~$375K from Health~Holland to collaborate with LUMC on research crucial for developing a new class of antibiotics against increasingly resistant pathogens. The initiative also explores potential biodefense applications.

HCW Biologics initiates a Phase 1 trial for HCW9302, leveraging groundbreaking research on regulatory T cells – work recently recognized with the Nobel Prize – to address the root cause of autoimmune hair loss.

Despite a slight revenue dip, Aurora Spine reports consecutive quarters of profitability fueled by new product launches. Can the company’s focus on minimally invasive solutions and proprietary tech drive sustained growth in a competitive market?

Record Q3 results for Cosmos Health Inc. showcase the power of its vertically integrated model and a surprising foray into digital assets. Analysts are watching closely as the company navigates a volatile market.

A renewed development push for acute pulmonary treatments could bring up to $78.9M to Windtree Therapeutics, offering a potential lifeline for the struggling biotech and new hope for premature infants.

WHO recognition of 'liraltagene autoleucel' marks a key milestone for Anixa Biosciences' innovative approach to treating recurrent ovarian cancer, offering a potential new hope for patients.

Medical device distributor Sharps Technology is making a bold move, shifting towards a Solana-based treasury and sparking debate about the risks and rewards of crypto adoption in traditional industries. A $411M financing fuels the transition.

New clinical data highlights the potential of Anteris Technologies’ DurAVR valve to address a critical need in patients with small aortic annuli, offering improved hemodynamics and reduced risk of complications.